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Abstract
Purpose of review—This work reviews recent research regarding treatment of fragile X 
syndrome (FXS), the most common inherited cause of intellectual disability and autism spectrum 
disorder. The phenotype includes anxiety linked to sensory hyperarousal, hyperactivity, and 
attentional problems consistent with attention deficit hyperactivity disorder and social deficits 
leading to autism spectrum disorder in 60% of boys and 25% of girls with FXS.
Recent findings—Multiple targeted treatments for FXS have rescued the phenotype of the fmr1 
knockout mouse, but few have been beneficial to patients with FXS. The failure of the 
metabotropic glutamate receptor 5 antagonists falls on the heels of the failure of Arbaclofen’s 
efficacy in children and adults with autism or FXS. In contrast, efficacy has been demonstrated in 
a controlled trial of minocycline in children with FXS. Minocycline lowers the abnormally 
elevated levels of matrix metalloproteinase 9 in FXS. Acamprosate and lovastatin have been 
beneficial in open-label trials in FXS. The first 5 years of life may be the most efficacious time for 
intervention when combined with behavioral and/or educational interventions.
Summary—Minocycline, acamprosate, lovastatin, and sertraline are treatments that can be 
currently prescribed and have shown benefit in children with FXS. Use of combined medical and 
behavioral interventions will likely be most efficacious for the treatment of FXS.
Keywords
fragile X syndrome; GABA agonists; mGluR5 antagonists; minocycline; omega 3; sertraline
Correspondence to Randi J. Hagerman, MD, Medical Director of the MIND Institute, Endowed Chair in Fragile X Research, UC 
Davis Health System, 2825 50th Street, Sacramento, CA 95817, USA. Tel: +1 916 703 0247; fax: +1 916 703 0240; 
randi.hagerman@ucdmc.ucdavis.edu. 
Conflicts of interest
Randi Hagerman has received funding from Novartis, Roche/Genentech, Seaside Therapeutics Neurpharm, Curemark, Forest, and 
Alcobra for treatment studies in fragile X syndrome, autism and Down’s syndrome. She has also consulted with Roche/Genentech, 
Novartis, and Alcobra regarding treatment studies in Fragile X syndrome. Jonathan Polussa does not have any conflicts.
HHS Public Access
Author manuscript
Curr Opin Psychiatry. Author manuscript; available in PMC 2018 August 09.
Published in final edited form as:






















Fragile X syndrome (FXS) has led the way for targeted treatments regarding 
neurodevelopmental disorders [1]. Perhaps, this is because the gene and causative mutation, 
the Cytosine, Guanine, Guanine (CGG) expansion in FMR1 was discovered in 1991, and the 
knockout mouse model for FXS was developed early so that the last decade of research has 
assessed new treatments that target the neurobiological abnormalities of FXS. This most 
common cause of intellectual disability and autism is caused by a full mutation in FMR1, 
meaning greater than 200 CGG repeats in the promoter region leading to methylation and 
the silencing of transcription. Since FMR1 is at Xq27.3, FXS is a sex-linked disorder and 
men are affected more severely than women. The dysmorphic facial features include narrow 
face and prominent ears, recently reviewed by Heulens et al. [2], although for many, these 
features may be hard to distinguish from the general population. Over 85% of men will have 
an intelligence quotient (IQ) between 20 and 70, whereas only 25% of women will have 
intellectual disability with an IQ less than 70. However, learning disabilities are seen in over 
70% of women and psychiatric problems including anxiety, compulsive behaviour, and 
attention deficit hyperactivity disorder (ADHD) are seen in the majority of men and women 
with FXS [3].
Anxiety is a key feature in FXS and in comparison to age-matched boys with autism without 
FXS anxiety was higher in those with FXS and there was a significant association between 
social avoidance and autism in FXS that was not seen in those with autism without FXS 
[4▪▪]. Autism spectrum disorder (ASD) occurs in approximately 60% of boys and 20% of 
girls [3,4▪▪]; however, boys with FXS and autism demonstrated a greater interest in social 
interactions than boys with autism without FXS, but overall more anxiety [4▪▪]. Therefore, 
anxiety is an important target for treatment in FXS.
Fragile X mental retardation 1 protein (FMRP), the protein normally produced by FMR1, 
but deficient or missing in FXS, is a regulator of translation that controls most of the 
proteins important for synaptic plasticity [5]. There is significant overlap between the genes 
associated with ASD and the genes whose translation is controlled by FMRP [6▪▪,7]. When 
FMRP is deficient, there is up-regulation of many proteins, including those that internalize 
AMPA receptors leading to enhanced long term depression (LTD), in addition to matrix 
metalloproteinase 9 (MMP9) that is important for synapse formation, GSK3β, Arc, STEP, 
Map1B, αCaMKII, post synaptic density 95, Shank 1, SAPAP1-3, and many others [6▪▪,8]. 
Dendritic spine morphology is dysregulated in FXS, leading to immature, elongated spines 
[9▪] that can be rescued by targeted treatments described below.
The metabotropic glutamate receptor 5 (mGluR5) theory of intellectual disability in FXS 
explained the immature synaptic connections seen in both animal models and humans with 
FXS as secondary to enhanced LTD produced by up-regulation of LTD proteins that 
internalized AMPA receptors and weakened the synaptic connections [8]. This theory led to 
the treatment of FXS by mGluR5 antagonists which would reverse the LTD and rescue the 
synaptic phenotype in FXS. Such was the case in the animal models that were treated with 
mGluR5 antagonists including MPEP, fenobam, AFQ056 (Mavoglurant; Novartis 
pharmaceuticals), and RO491756 (Basimglurant; Hoffman-LaRoche pharmaceuticals) 
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[8,10]. However, the human trials discussed below have not met efficacy criteria and 
therefore further studies have been stopped in 2014.
The gamma amino butyric acid (GABA) system is basically down-regulated in FXS and this 
has led to the use of GABAA and GABAB agonists in both animal models and human trials 
in FXS. The preliminary study of Arbaclofen (STX209) demonstrated benefit in a subgroup 
of patients with FXS, particularly those with ASD or social avoidance on the Aberrant 
Behavior Checklist (ABC) [11]. Therefore, a subsequent phase 2 open-label trial was 
initiated to assess long-term benefit, and two phase 3 multicenter studies were initiated in 
both adolescents and adults (209FX301; aged 12–50; n = 120; Clinical Trials.gov identifier: 
NCT01282268) and in children aged 5–11 years (209FX302; n =172; Clinical Trials.gov 
identifier: NCT01325220). These studies involved 8 weeks of treatment vs. placebo, with 
the first 4 weeks involving escalation of the dose followed by 4 weeks of stable dose of 
Arbaclofen/placebo (maximal dose was 10 mg three times a day). The phase 2 controlled 
trial in ASD without FXS did not demonstrate efficacy on the primary outcome measure and 
the publicity of the failed autism trial led to failure of the company financially and the 
fragile X trials were halted. The results of the two phase 3 controlled trials were presented at 
the National Fragile X Foundation International Conference in Anaheim in July 2014 [12]. 
Neither of the phase 3 trials of FXS met their primary outcome measure of significant 
improvement in Social Avoidance Scale on the fragile X ABC [13] that had demonstrated a 
beneficial outcome in the initial phase 2 trial once the data were reanalyzed. However, the 
children’s trial (209FX302) demonstrated significant efficacy on secondary measures, so it 
appears that Arbaclofen may be more effective in young children with FXS, although it is 
currently unavailable.
Ganaxolone, a neurosteroid that is a GABAa agonist is in a phase 2 double-blind crossover 
trial in children with FXS aged 6–17 years at the MIND Institute (http://
www.clinicaltrials.gov; NCT01725152), but results will not be known for another year.
Additional agents have been tried in children with FXS including minocycline and sertraline, 
with good results reviewed below. Up-and-coming agents have been introduced this year in 
animal studies, and these results which will eventually move into clinical trials are discussed 
below.
MINOCYCLINE
Minocycline is an antibiotic used in the treatment of acne in adolescence. Minocycline 
lowers MMP9 level that is too high in FXS [14▪]. The recent publication of a double-blind 
crossover controlled trial of minocycline lasting 3 months for each arm of treatment was 
carried out in 55 children aged 3.5–16 years with FXS. Forty-eight patients completed this 
trial and efficacy was demonstrated on the primary outcome measure of the Clinical Global 
Impression Scale (CGI-I) and on the secondary measure of the Visual Analogue Scale (VAS) 
targeting mood and anxiety [15▪]. Side-effects were not significantly different compared to 
placebo in this study. However, minocycline can cause graying of the permanent teeth and 
sometimes darkening of the nails, skin, or gums with long-term use. In addition, a positive 
antinuclear antibody (ANA) can occur in a subgroup of patients treated with minocycline, so 
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the ANA should be checked every 6 months to 1 year for safety. A rare side-effect of a 
lupus-like syndrome with rash and swollen joints can develop with minocycline treatment. 
Another rare side-effect includes headaches caused by pseudotumor cerebri, meaning 
increased intracranial pressure. Minocycline is available clinically and can be prescribed for 
those with FXS, but families should be warned that if headache, rash, swollen joints, or an 
increasing ANA titer develop, then the minocycline should be discontinued. Event-related 
potential (ERP) studies have demonstrated improvements in habituation to a passive odd ball 
auditory paradigm in 12 patients with FXS (eight males and four females; mean age 10.5 
years) who underwent the minocycline controlled trial [16▪▪]. After 3 months of minocycline 
treatment, the elevated N1 and P2 amplitudes over the temporal regions typical for FXS 
normalized and habituation significantly improved compared to placebo [16▪▪]. This study 
demonstrates that ERPs are a sensitive and feasible biomarker that can be utilized as an 
outcome measure in treatment trials in children with FXS.
The very recent report of the cross between an MMP9 knockout mouse with an fmr1 
knockout mouse leading to the rescue of the FXS phenotype in the offspring emphasizes the 
importance of the MMP9 pathway in the phenotype of FXS [17▪]. Therefore, further studies 
are needed in young children with FXS who are treated early so that the appropriate synaptic 
connections can be developed early on.
LOVASTATIN
The recent study by Osterweil et al. [18▪▪] represents another targeted treatment that can 
down-regulate the excessive protein synthesis that occurs in FXS. They studied the enhanced 
activity of the Ras/MAPK pathway in FXS and found that lovastatin, an HMG-CoA 
reductase inhibitor used to treat hypercholesterolemia in children and adults, can correct 
excessive Ras activity in the fmr1 knockout mouse model similar to what lovastatin can do 
in the mouse model of neurofibromatosis (NF1). They demonstrated that lovastatin treatment 
corrected the excessive extra cellular receptor kinase-mediated protein synthesis and blocked 
mGluR5-mediated epileptiform bursting in the fmr1 knockout hippocampal neurons. 
Lovastatin also dampened the hyperexcitability seen in the visual cortex in the knockout 
mouse. In addition, they rescued the seizure phenotype in the live knockout mouse. These 
studies have stimulated human trials of lovastatin and preliminary results of an open-label 
trial in children with FXS in Canada demonstrated positive results [19].
ACAMPROSATE
Acamprosate is a GABAa agonist that is US Food and Drug Administration (FDA)-approved 
for maintenance of abstinence in adults with alcohol dependence. However, acamprosate has 
potential antagonism at mGluR5 receptors with similar effects to mGluR5 antagonists in the 
rodent models of alcoholism [20]. Acamprosate also binds at spermidine-sensitive NMDA 
glutamate receptors where it can enhance activation at low glutamate concentrations and 
cause inhibition at high glutamate concentrations. Erickson et al. [21] initially carried out an 
open-label study in three young adults with FXS and saw not only improvements in the 
CGI-I in all patients but unexpected improvements in language. They have recently reported 
a 10-week open-label acamprosate trial in 12 children (6–17 years; mean age 11.9 years) 
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with FXS. Nine of the 12 children (75%) demonstrated significant improvement in the CGI-I 
and additional standardized scales improved capturing benefits in ADHD symptoms and 
social interactions. They also demonstrated a deficit in brain derived neurotropic factor 
(BDNF) measured in blood at baseline and they saw a significant increase in this biomarker 
with acamprosate treatment, although the improvement in BDNF levels did not correlate 
with treatment response measures [22▪]. Currently, a multicenter controlled trial of 
acamprosate is being carried out in individuals with FXS (http://www.clinicaltrials.gov; 
NCT01911455).
CANNABINOIDS
The endocannabinoid system is a modulator of synaptic plasticity, anxiety, and seizure 
activity, and Maccarrone et al. [23,24] were the first to show that FMRP is a regulator of the 
endocannabinoid system in the striatum. Pharmacological blockade of the endocannabinoid 
receptor CBR1 by rimonabant has been shown to normalize cognitive impairment, reduce 
susceptibility to seizures, and normalize mammalian target of rapamycin (mTOR) signaling 
in knockout mice [25▪]. Recent study by Straiker et al. [26] have demonstrated broad effects 
on the endocannabinoid system by the loss of FMRP in the knockout mouse that changes 
with age. Initially, there appears to be overproduction of the 2-arach-idonoylglycerol (2AG) 
neurotransmitter leading to enhanced cannabinoid inhibition of excitatory neurotransmission 
in hippocampal neuron of the knockout mouse; then there is a gradual desensitization of 
CB1 receptors with age and a decline in cannabinoid signaling [26]. Although there appears 
to be the potential for therapeutic manipulation of the cannabinoid system in FXS, there is 
no consensus regarding whether a blockade or enhancement of one or the other receptor 
(CB1 or CB2) and the appropriate age that would be acceptable for studies of patients with 
FXS.
OMEGA 3 AND OTHER NEUTRACEUTICALS
There is significant evidence from knockout mouse studies that additives to the diet 
including alpha-tocopherol (vitamin E) and N-acetyl cysteine (NAC) [27], melatonin (also 
an antioxidant) [28] and just recently long chain polyunsaturated fatty acids (PUFAs or 
omega 3s) can rescue some of the phenotypic abnormalities seen in FXS [29▪▪]. Presumably 
these benefits with antioxidants are related to the enhanced oxidative stress seen in the 
knockout mice [30]. The omega 3 study supplemented knockout mice from the time of 
weaning to adulthood with a diet enriched with omega 3s, including more n-3 long-chain 
PUFAs such as 20:5 n-3 (eicosapentaenoic acid), 22:6 n-3 (docosahexaenoic acid) compared 
to the control diet, which was isocaloric with equal amounts of lipid including a normal 
amount of PUFAs. The PUFA-enriched diet in the knockout mice led to improvement in the 
affiliation deficit when interacting with female mice, improvement in excessive self-
grooming, changes in various cytokine/chemokine levels, and normalization of the BDNF 
deficit seen in the dentate gyrus of the knockout mice compared to control mice [29▪▪]. 
These findings are compelling because such supplements are easy to recommend, although 
studies of patients with FXS have not been completed. A randomized controlled trial of 
alpha tocopherol (10 mg/kg/day) combined with vitamin C (10 mg/kg/day) is currently 
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being carried out in Spain by de Diego-Otero et al. [31] lasting 12–24 weeks for boys with 
FXS aged 6–18 years (ClinicalTrials.gov Identifier: NCT01329770).
SELECTIVE SEROTONIN REUPTAKE INHIBITORS
Metabolomic studies show down-regulation of the enzymes that metabolize tryptophan to 
serotonin in the blood of individuals with both genetic and idiopathic forms of ASD [32]. 
Further evidence of serotonin deficits have been found in positive electron tomography 
studies of children with autism between the age of 2 and 6 years [33]. Such studies and 
clinical experience led to the treatment of young children with FXS with sertraline to 
improve anxiety, sensory hyperarousal, and language deficits [34]. In a retrospective review 
of 45 patients with FXS (18 months to 6 years), there was a significant benefit in the 
trajectory of both receptive and expressive language as measured by the Mullen Scales of 
Early Learning (MSEL) in those treated with sertraline compared to those not treated with 
sertraline [34]. These data stimulated a controlled trial of low-dose sertraline (2.5–5.0 mg/
day) treatment in young children with FXS between the age of 24–68 months at the MIND 
Institute (Clinical-Trials.gov identifier: NCT01474746). Preliminary data after the first 30 
children completed the study demonstrated significant improvement on the CGI-I in those 
treated with sertraline [35]. Selective serotonin reuptake inhibitors (SSRIs) are known to 
stimulate neurogenesis and increase BDNF which is low in FXS [36]. In addition, sertraline 
specifically enhances dopamine levels in the striatum [37] and has neuroprotective and 
procognitive effects in young mice [38]. Both of these strengths can be very important for 
young children with FXS who have evidence of oxidative stress.
ENVIRONMENTAL ENRICHMENT
A recently published paper by Oddi et al. [39▪▪] has demonstrated that enrichment in early 
development in the knockout mouse by the introduction of a nonlactating female to the 
mother– pup pair from birth to 3 months of age had significant positive effects on the time 
the mother spent with the babies and also on the adult phenotype of the knockout mouse. 
Specifically, this enriched environment eliminated the hyperactivity, rescued the social 
deficits, and eliminated the cognitive deficits in two hippocampal phenotypes, the Y maze 
and the contextual freezing deficits in the adult knockout mouse. In addition, there was 
rescue of the immature spine morphology in apical and basal dendrites in the hippocampus 
in the adult knockout mouse [39▪▪]. This work points to the importance of early intervention 
and builds on the previous work of environmental enrichment through physical toys [40] by 
showing that another adult, apart from the mother, is an important form of enrichment. This 
enrichment is reminiscent of the benefits of early intervention with a therapist who can 
enhance the mother’s interaction with her child as is seen in the Early Start Denver Model 
with long-lasting consequences in children with autism [41].
COMBINATION TREATMENTS
An exciting result in the knockout mouse model was published in 2014 by Lim et al. [42▪], 
demonstrating that combining low-dose serotonin 5 HT2B agonist with a dopamine (DA-1) 
agonist led to improvements in normalizing protein kinase B (PKB) signaling and rescued 
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the associative learning deficit in the knockout mouse compared to controls. Basically, the 
NMDA-R-dependent long-term potentiation (LTP) is reduced in the knockout mouse [43] 
due to a selective impairment of signal transduction between Ras and P13K/PKB that 
impairs GluA1-dependent plasticity in the knockout mouse [44]. It has been known for years 
that children with FXS respond best to low doses of stimulants combined with an SSRI, 
typically sertraline [45], and now the animal studies demonstrate that this cocktail works 
best in a low dose compared to a high dose. In the absence of FMRP, many of the proteins 
belonging to the NMDA-R–Ras–PI3K/PKB signaling interactome are dysregulated [6▪▪,
42▪]. Lim et al. show that synaptic Ras signal transduction is impaired even though the basal 
Ras activity is up-regulated in knockout mice. Knockout mice have reduced maximal 
PI3K/PKB activity compared to wild-type mice. The rescue of synaptic plasticity and 
associative learning with the cocktail occurred via stimulating PI3K/PKB signaling 
dynamics and thus restoring PI3K/PKB signaling-dependent synaptic GluA1 trafficking. 
This GluA1-dependent rescue is consistent with the findings that the knockout mice have a 
predominant deficit in GluA1-dependent synaptic plasticity [44] and synaptic GluA1 
delivery is required for associative learning [42▪].
Seese et al. have also recently demonstrated that the spacing of learning trials also has a 
profound effect on long-term memory in the knockout mouse [46]. Instead of one long 
training session which promotes LTP in the wild-type mouse, the knockout mouse has robust 
long-term memory only when the training is divided into three short sessions each separated 
by 1 h. This basic research should be translated into the school for those with FXS.
CONCLUSION
The concept of combined treatments working best in FXS will likely be studied further, 
particularly combining medications that have different mechanisms of action, for example, 
minocycline and ganaxolone or minocycline and sertraline [47]. In addition, expanding 
combinations to include medications that will improve synaptic plasticity with innovative 
learning programs is essential if reversal of cognitive and behavioral impairment is to be 
achieved in FXS [48]. An example of an intensive learning program that is helpful for 
ADHD symptoms in children with FXS is CogMed, a digital program for improving 
attention and learning in children with ADHD [49]. Another example is an intensive digital 
reading program, such as Head-Sprout, because the enhancement of reading can be 
important for improving the verbal IQ in children with FXS [50]. We are in a new age for 
improving cognitive and behavioral problems in those with neurodevelopmental disorders 
and the plethora of new targeted treatments for many disorders in addition to FXS, such as 
Rett syndrome, ASD, Down’s syndrome, and many others will dramatically increase in the 
next few years [51].
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• Minocycline is available by prescription and has demonstrated efficacy for 
improving behavior in children with FXS.
• The mGluR5 antagonists have not demonstrated efficacy in controlled trials in 
FXS.
• There is both animal evidence and clinical evidence that combining 
treatments, such as the use of a stimulant and an SSRI, can be helpful in the 
treatment of FXS.
• Research regarding the combined effects of behavioral/learning intervention 
and medication intervention is greatly needed in the fragile X field.
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